Imagen de portada del programa Therapeutic Momentum

Therapeutic Momentum

Podcast de Therapeutic Momentum

inglés

Negocios

$99 / mes después de la prueba. Cancela cuando quieras.

  • 20 horas de audiolibros al mes
  • Podcasts solo en Podimo
  • Podcast gratuitos

Acerca de Therapeutic Momentum

The Therapeutic Momentum podcast series illuminates the inspiring personal stories, touchstone moments, and transformational events that fuel the relentless pursuit of life-changing treatments. It reveals the intricate tapestry of experiences that drive people in the biomedical field who share the collective goal of improving patient outcomes. We hope to offer listeners a multifaceted perspective on the diverse talent and backgrounds of people working towards better health and hope for patients.

Todos los episodios

8 episodios

episode Kate Haviland: The Bilingual Biotech Leader Behind Blueprint's $9.5B Sanofi Deal artwork

Kate Haviland: The Bilingual Biotech Leader Behind Blueprint's $9.5B Sanofi Deal

In this episode I am joined by Kate Haviland, who most recently served as President and CEO of Blueprint Medicines, guiding it from a clinical-stage company through a fully integrated commercial business and ultimately through its roughly $9.5 billion acquisition by Sanofi in 2025. Over a more than twenty-year career spanning Genzyme, PTC Therapeutics, Sarepta, Idera, and Blueprint, Kate has built a reputation for bridging rigorous science with sharp business instincts, equally fluent in the lab and the boardroom. She studied biochemistry and economics at Wesleyan, earned her MBA at Harvard Business School, and today serves as Board Chair of both Fulcrum Therapeutics and GC Therapeutics, as a director at Bicara and Avalyn, and on the board of BIO. This episode was recorded in 2025

16 de may de 2026 - 53 min
episode AI + Life Sciences: Why the Future Needs Both Human Brains and Wet Labs artwork

AI + Life Sciences: Why the Future Needs Both Human Brains and Wet Labs

In this episode, I speak with Sam Scarpino, Director of AI and Life Sciences at Northeastern University's Institute for Experiential AI and Professor of Public Health and Health Sciences. With a background spanning evolutionary biology, pandemic response during H1N1, and pathogen surveillance at the Rockefeller Foundation, Sam offers a distinctive perspective on artificial intelligence in the life sciences. We discuss the fundamental limitations of AI in biological systems, the irreplaceable role of wet lab experimentation, and how human-AI collaboration can address challenges from rural oncology access to rare disease drug development. Sam also shares his views on why current debates around AGI distract from the urgent work of building responsible AI tools today.

11 de abr de 2026 - 57 min
episode Mathai Mammen - Motivated by Math, Medicine & Memories artwork

Mathai Mammen - Motivated by Math, Medicine & Memories

Mathai Mammen is a world-renowned innovator in drug discovery, development, and team- and company-building responsible for creating 13 transformational medicines from discovery through commercial launch and more than 25 other potential medicines that have achieved clinical proof-of-concept, many of these practice-changing. Mathai is the CEO, President and Chairman of Cambridge-based Parabilis Medicines, a clinical-stage biopharmaceutical company advancing a new category of peptide therapeutics for people affected by cancer and other severe diseases. Previously Mathai was Executive Vice President of Pharmaceuticals, R&D at Johnson & Johnson, one of the largest R&D organizations in the world. Prior to that Mathai was the leader of much of the research at Merck including Oncology, Immunology and Cardiovascular Disease. He began his career as head of R&D at Theravance, Inc., a company he co-founded out of graduate school based on his work at Harvard University with Dr. George Whitesides, which split to form Theravance Biopharma and Innoviva. Mathai holds an M.D. from the Harvard Medical School and Massachusetts Institute of Technology (HST) and a Ph.D. in chemistry from Harvard University.

20 de jul de 2025 - 1 h 8 min
Muy buenos Podcasts , entretenido y con historias educativas y divertidas depende de lo que cada uno busque. Yo lo suelo usar en el trabajo ya que estoy muchas horas y necesito cancelar el ruido de al rededor , Auriculares y a disfrutar ..!!
Muy buenos Podcasts , entretenido y con historias educativas y divertidas depende de lo que cada uno busque. Yo lo suelo usar en el trabajo ya que estoy muchas horas y necesito cancelar el ruido de al rededor , Auriculares y a disfrutar ..!!
Fantástica aplicación. Yo solo uso los podcast. Por un precio módico los tienes variados y cada vez más.
Me encanta la app, concentra los mejores podcast y bueno ya era ora de pagarles a todos estos creadores de contenido

Elige tu suscripción

Más populares

Premium

20 horas de audiolibros

  • Podcasts solo en Podimo

  • Disfruta los shows de Podimo sin anuncios

  • Cancela cuando quieras

Empieza 7 días de prueba
Después $99 / mes

Prueba gratis

Sólo en Podimo

Audiolibros populares

Prueba gratis

Empieza 7 días de prueba. $99 / mes después de la prueba. Cancela cuando quieras.